GPP
CNTX icon

Great Point Partners’s Context Therapeutics CNTX Stock Holding History

Great Point Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,238,496
Closed -$5.86M – 48
2026
Q1 		$5.86M Sell
2,238,496
-2,445,215
-52% -$5.71M 1.35% 27
2025
Q4 		$6.89M Hold
4,683,711
– – 2.23% 19
2025
Q3 		$4.54M Hold
4,683,711
– – 1.87% 20
2025
Q2 		$3.07M Hold
4,683,711
– – 2% 21
2025
Q1 		$2.87M Hold
4,683,711
– – 1.52% 26
2024
Q4 		$4.92M Sell
4,683,711
-2,251,271
-32% -$3.9M 2.32% 19
2024
Q3 		$13.6M Sell
6,934,982
-484,373
-7% -$1.07M 4% 9
2024
Q2 		$14.9M Buy
+7,419,355
New +$12.8M 2.85% 15

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Great Point Partners's CNTX Position: Q2 2026 in Review

Great Point Partners sold out of Context Therapeutics (CNTX) in Q2 2026, closing a stake of 2,238,496 shares — an estimated $5.86M sold.

Great Point Partners first reported a position in CNTX in Q2 2024 and held it in 8 quarters. The position peaked at $14.9M in Q2 2024. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Great Point Partners reported no remaining Context Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Great Point Partners sold 2,238,496 Context Therapeutics shares in Q2 2026, an estimated $5.86M.
  • Great Point Partners first reported a position in Context Therapeutics in Q2 2024 and held it in 8 quarters.
  • Great Point Partners's Context Therapeutics position peaked at $14.9M in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.